| NICE Cancer Service Guideline |
Improving outcomes in breast cancer CSG1 |
| NICE Clinical Guidance |
Advanced breast cancer: diagnosis and treatment CG81 |
| NICE Clinical Guideline |
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer CG164 |
| NICE Diagnostics Guidance |
Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer DG8 |
| NICE Diagnostics Guidance |
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer DG34 |
| NICE Guideline |
Early and locally advanced breast cancer: diagnosis and management NG101 |
| NICE Guideline |
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer TA509 |
| NICE Medical Technologies Guidance |
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer MTG72 |
| NICE Interventional Procedures Guidance |
Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision IPG268 |
| NICE Interventional Procedures Guidance |
Breast reconstruction using lipomodeling after breast cancer treatment IPG417 |
| NICE Interventional Procedures Guidance |
Endoscopic axillary lymph node retrieval for breast cancer IPG147 |
| NICE Interventional Procedures Guidance |
Endoscopic mastectomy and endoscopic wide local excision for breast cancer IPG296 |
| NICE Interventional Procedures Guidance |
Interstitial laser therapy for breast cancer IPG89 |
| NICE Technology Appraisal Guidance |
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receotor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence TA810 |
| NICE Technology Appraisal Guidance |
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA563 |
| NICE Technology Appraisal Guidance |
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy TA725 |
| NICE Technology Appraisal Guidance |
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer TA816 |
| NICE Technology Appraisal Guidance |
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer TA639 |
| NICE Technology Appraisal Guidance |
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA214 |
| NICE Technology Appraisal Guidance |
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer TA263 |
| NICE Technology Appraisal Guidance |
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen TA515 |
| NICE Technology Appraisal Guidance |
Eribulin for treating locally advanced or metastatic breast cancer after two or more chemotherapy regimens TA423 |
| NICE Technology Appraisal Guidance |
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy TA421 |
| NICE Technology Appraisal Guidance |
Fulvestrant for the treatment of locally advanced or metastatic breast cancer TA239 |
| NICE Technology Appraisal Guidance |
Gemcitabine for the treatment of metastatic breast cancer TA116 |
| NICE Technology Appraisal Guidance |
Guidance on the user of trastuzumab for the treatment of advanced breast cancer TA34 |
| NICE Technology Appraisal Guidance |
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer TA501 |
| NICE Technology Appraisal Guidance |
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 TA257 |
| NICE Technology Appraisal Guidance |
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab TA612 |
| NICE Technology Appraisal Guidance |
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy TA886 |
| NICE Technology Appraisal Guidance |
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA495 |
| NICE Technology Appraisal Guidance |
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy TA836 |
| NICE Technology Appraisal Guidance |
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer TA851 |
| NICE Technology Appraisal Guidance |
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer TA801 |
| NICE Technology Appraisal Guidance |
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer TA569 |
| NICE Technology Appraisal Guidance |
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer TA424 |
| NICE Technology Appraisal Guidance |
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA496 |
| NICE Technology Appraisal Guidance |
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy TA687 |
| NICE Technology Appraisal Guidance |
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies TA819 |
| NICE Technology Appraisal Guidance |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments TA862 |
| NICE Technology Appraisal Guidance |
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer TA632 |
| NICE Technology Appraisal Guidance |
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane TA458 |
| NICE Technology Appraisal Guidance |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies TA704 |
| NICE Technology Appraisal Guidance |
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies TA786 |
